CHU Bretonneau
CHU Bretonneau
Tours, France10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT03462719 | |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | acute leukemia | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT04811560 | |
| COsegregation of VARiants in Panel of Genes | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, disease susceptibility, inherited disease susceptibility | Recruiting | Not applicable | 2026-09-01 | NCT01689584 | |
| Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-08-28 | NCT04802590 | |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Infections, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, basal cell carcinoma, basal cell neoplasm, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervix disorder, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, head and neck cancer, hepatocellular carcinoma, kidney cancer, kidney disorder, liver disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, renal cell carcinoma, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm, transitional cell carcinoma, triple-negative breast carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder, viral infectious disease | Active, not recruiting | Phase 3 | 2026-07-17 | NCT05078047 | |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-22 | NCT04595565 | |
| ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach | Amyotrophic Lateral Sclerosis, Sporadic, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, amyotrophic lateral sclerosis type 1, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Not stated | 2026-03-27 | NCT05928416 | |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | Non Small Cell Lung Cancer Metastatic | Active, not recruiting | Phase 2 | 2025-09-24 | NCT04621188 | |
| Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, neoplasm | Recruiting | Phase 3 | 2025-06-15 | NCT05874063 | |
| Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence | Breast Cancer Female | Active, not recruiting | Not applicable | 2024-04-09 | NCT03127995 |